Smolen JS, et al. - The aims of the present transition-extension period (depicted as transition period hereafter) of the phase III study were to research whether individuals on INF could be readily switched to SB2 without major concerns and whether comparable effectiveness, safety and immunogenicity were maintained after the switch when compared with both ongoing reference INF and also SB2. The effectiveness, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2.